Oculis Holding AG (OCS) Cash & Current Investments (2021 - 2026)
Quarterly Cash & Current Investments rose 83.07% to $304.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $304.9 million through Mar 2026, up 83.07% year-over-year, with the annual reading at $266.5 million for FY2025, 136.64% up from the prior year.
Oculis Holding AG's Cash & Current Investments history spans 6 years, with the latest figure at $304.9 million for Q1 2026.
- Cash & Current Investments came in at $304.9 million for Q1 2026, up from $266.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $304.9 million in Q1 2026 to a low of $20.5 million in Q4 2022.
- The 5-year median for Cash & Current Investments is $110.5 million (2023), against an average of $125.8 million.
- Year-over-year, Cash & Current Investments crashed 59.08% in 2022 and then surged 402.89% in 2024.
- Oculis Holding AG's Cash & Current Investments stood at $20.5 million in 2022, then skyrocketed by 301.3% to $82.4 million in 2023, then surged by 36.65% to $112.6 million in 2024, then skyrocketed by 136.64% to $266.5 million in 2025, then rose by 14.42% to $304.9 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Cash & Current Investments are $304.9 million (Q1 2026), $266.5 million (Q4 2025), and $181.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 8.75 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 304.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.95 Mn |
| Dec 31, 2025 | 266.52 Mn |
| Sep 30, 2025 | 181.49 Mn |
| Jun 30, 2025 | 193.62 Mn |
| Mar 31, 2025 | 166.57 Mn |
| Dec 31, 2024 | 112.63 Mn |
| Sep 30, 2024 | 124.85 Mn |
| Jun 30, 2024 | 124.29 Mn |
| Mar 31, 2024 | 107.58 Mn |
| Dec 31, 2023 | 82.42 Mn |
| Sep 30, 2023 | 108.30 Mn |
| Jun 30, 2023 | 102.17 Mn |
| Mar 31, 2023 | 21.39 Mn |
| Dec 31, 2022 | 20.54 Mn |
| Sep 30, 2022 | 47.92 Mn |
| Jun 30, 2022 | 48.05 Mn |
| Dec 31, 2021 | 50.19 Mn |